# Cyabra, Inc.: financial statements, quarterly

CYAB · Nasdaq · CIK 2032341 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cyab.md) · [Financials](/companies/cyab/financials.md) · [Filings](/companies/cyab/filings.md) · [Insiders](/companies/cyab/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cyab/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Revenue | $m | [1.3](/filings/0001213900-26-057819.md) | [1.3](/filings/0001213900-26-088752.md) | [1.4](/filings/0001213900-26-057819.md) | [1.9](/filings/0001213900-26-088752.md) |
| Cost of revenue | $m | [0.2](/filings/0001213900-26-057819.md) | [0.2](/filings/0001213900-26-088752.md) | [0.2](/filings/0001213900-26-057819.md) | [0.3](/filings/0001213900-26-088752.md) |
| Gross profit | $m | [1.1](/filings/0001213900-26-057819.md) | [1.1](/filings/0001213900-26-088752.md) | [1.2](/filings/0001213900-26-057819.md) | [1.5](/filings/0001213900-26-088752.md) |
| Research and development | $m | [1.9](/filings/0001213900-26-057819.md) | [1.8](/filings/0001213900-26-088752.md) | [5.5](/filings/0001213900-26-057819.md) | [2.1](/filings/0001213900-26-088752.md) |
| Operating income | $m | [(4.0)](/filings/0001213900-26-057819.md) | [(3.4)](/filings/0001213900-26-088752.md) | [(11.8)](/filings/0001213900-26-057819.md) | [(3.1)](/filings/0001213900-26-088752.md) |
| Income tax | $m | not reported | [0.0](/filings/0001213900-26-088752.md) | not reported | [0.1](/filings/0001213900-26-088752.md) |
| Net income | $m | [(3.3)](/filings/0001213900-26-057819.md) | [(2.4)](/filings/0001213900-26-088752.md) | [(10.8)](/filings/0001213900-26-057819.md) | [(3.4)](/filings/0001213900-26-088752.md) |
| Diluted EPS | $ per share | [(1.47)](/filings/0001213900-26-057819.md) | [(1.07)](/filings/0001213900-26-088752.md) | [(3.10)](/filings/0001213900-26-057819.md) | [(0.26)](/filings/0001213900-26-088752.md) |
| Basic EPS | $ per share | [(1.47)](/filings/0001213900-26-057819.md) | [(1.07)](/filings/0001213900-26-088752.md) | [(3.10)](/filings/0001213900-26-057819.md) | [(0.26)](/filings/0001213900-26-088752.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2024-12-31) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | [0.7](/filings/0001213900-26-057819.md) | [0.2](/filings/0001213900-26-088752.md) | [0.3](/filings/0001213900-26-088752.md) | [3.1](/filings/0001213900-26-057819.md) | [0.8](/filings/0001213900-26-088752.md) |
| Current assets | $m | not reported | not reported | not reported | [0.7](/filings/0001213900-26-088752.md) | [3.8](/filings/0001213900-26-057819.md) | [2.0](/filings/0001213900-26-088752.md) |
| Total assets | $m | not reported | not reported | not reported | [1.5](/filings/0001213900-26-088752.md) | [4.5](/filings/0001213900-26-057819.md) | [2.6](/filings/0001213900-26-088752.md) |
| Current liabilities | $m | [0.1](/filings/0001213900-26-034218.md) | not reported | not reported | [25.5](/filings/0001213900-26-088752.md) | [16.4](/filings/0001213900-26-057819.md) | [13.9](/filings/0001213900-26-088752.md) |
| Total liabilities | $m | not reported | not reported | not reported | [26.2](/filings/0001213900-26-088752.md) | [16.6](/filings/0001213900-26-057819.md) | [14.6](/filings/0001213900-26-088752.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | [5.8](/filings/0001213900-26-088752.md) | [2.2](/filings/0001213900-26-057819.md) | [2.0](/filings/0001213900-26-088752.md) |
| Shareholders' equity | $m | [(30.4)](/filings/0001213900-26-088752.md) | [(32.3)](/filings/0001213900-26-088752.md) | [(33.9)](/filings/0001213900-26-088752.md) | [(40.0)](/filings/0001213900-26-088752.md) | [(12.0)](/filings/0001213900-26-088752.md) | [(12.0)](/filings/0001213900-26-088752.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,273)](/filings/0001213900-26-057819.md) | [(2,560) d](/filings/0001213900-26-088752.md) | [(2,598)](/filings/0001213900-26-057819.md) | [(2,397) d](/filings/0001213900-26-088752.md) |
| Capital expenditure | $k | [12.0](/filings/0001213900-26-057819.md) | [17.0 d](/filings/0001213900-26-088752.md) | [5.0](/filings/0001213900-26-057819.md) | [23.0 d](/filings/0001213900-26-088752.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [2.4](/filings/0001213900-26-057819.md) | [2.4](/filings/0001213900-26-088752.md) | [3.5](/filings/0001213900-26-057819.md) | [13.8](/filings/0001213900-26-088752.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 17,597,071 at 2026-08-12, from the cover of the [10-Q filed 2026-08-13](/filings/0001213900-26-088752.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:51 ET. No prices; not investment advice.